Biomarin Pharmaceutical Inc (NASDAQ:BMRN) — Market Cap & Net Worth

$12.51 Billion USD · Rank #1879

Market Cap & Net Worth: Biomarin Pharmaceutical Inc (BMRN)

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) has a market capitalization of $12.51 Billion ($12.51 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1879 globally and #710 in its home market, demonstrating a 0.15% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomarin Pharmaceutical Inc's stock price $64.73 by its total outstanding shares 193573759 (193.57 Million). Also see Biomarin Pharmaceutical Inc (BMRN) total assets for a full breakdown of the balance sheet.

Biomarin Pharmaceutical Inc Market Cap History: 2015 to 2026

Biomarin Pharmaceutical Inc's market capitalization history from 2015 to 2026. Data shows change from $20.28 Billion to $12.53 Billion (-4.52% CAGR). Also see BMRN cash flow metrics for how efficiently the company converts equity into cash flow.

Index Memberships

Biomarin Pharmaceutical Inc is a constituent of 6 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
ARCA Biotechnology BTK	$1.06 Trillion	1.18%	#18 of 30
Dow Jones Biotechnology DJUSBT	$1.16 Trillion	1.08%	#13 of 39
NASDAQ Health Care IXHC	$2.66 Trillion	0.47%	#35 of 976
NASDAQ Composite IXIC	$41.69 Trillion	0.03%	#217 of 3165
S&P Midcap 400 MID	$3.41 Trillion	0.43%	#64 of 401
NASDAQ Biotechnology NBI	$1.88 Trillion	0.67%	#26 of 263

Weight: Biomarin Pharmaceutical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Biomarin Pharmaceutical Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Biomarin Pharmaceutical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BMRN live share price for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

3.57x

Biomarin Pharmaceutical Inc's market cap is 3.57 times its annual revenue

Industry average: 3887.01x Lower than industry average

Latest Price to Earnings (P/E) Ratio

32.97x

Biomarin Pharmaceutical Inc's market cap is 32.97 times its annual earnings

Industry average: 1.67x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$16.04 Billion	$1.12 Billion	-$630.21 Million	14.36x	N/A
2017	$17.26 Billion	$1.31 Billion	-$117.04 Million	13.14x	N/A
2018	$16.48 Billion	$1.49 Billion	-$77.21 Million	11.05x	N/A
2019	$16.37 Billion	$1.70 Billion	-$23.85 Million	9.60x	N/A
2020	$16.97 Billion	$1.86 Billion	$854.03 Million	9.12x	19.88x
2021	$17.10 Billion	$1.85 Billion	-$64.08 Million	9.26x	N/A
2022	$20.03 Billion	$2.10 Billion	$141.56 Million	9.56x	141.51x
2023	$18.66 Billion	$2.42 Billion	$167.65 Million	7.72x	111.33x
2024	$12.72 Billion	$2.85 Billion	$426.86 Million	4.46x	29.81x
2025	$11.50 Billion	$3.22 Billion	$348.90 Million	3.57x	32.97x

Competitor Companies of BMRN by Market Capitalization

Companies near Biomarin Pharmaceutical Inc in the global market cap rankings as of September 17, 2026. Review BMRN goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Biomarin Pharmaceutical Inc by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#187	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$130.09 Billion	$513.26
#353	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$78.34 Billion	$774.61
#457	CSL Ltd	AU:CSL	$59.87 Billion	AU$174.41
#505	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$145.62

Biomarin Pharmaceutical Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Biomarin Pharmaceutical Inc's market cap moved from $20.28 Billion to $ 12.53 Billion, with a yearly change of -4.52%.

Year	Market Cap	Change (%)
2026	$12.53 Billion	+8.92%
2025	$11.50 Billion	-9.58%
2024	$12.72 Billion	-31.83%
2023	$18.66 Billion	-6.83%
2022	$20.03 Billion	+17.14%
2021	$17.10 Billion	+0.75%
2020	$16.97 Billion	+3.71%
2019	$16.37 Billion	-0.70%
2018	$16.48 Billion	-4.51%
2017	$17.26 Billion	+7.64%
2016	$16.04 Billion	-20.92%
2015	$20.28 Billion	--

End of Day Market Cap According to Different Sources

On Sep 17th, 2026 the market cap of Biomarin Pharmaceutical Inc was reported to be:

Source	Market Cap
Yahoo Finance	$12.51 Billion USD
MoneyControl	$12.51 Billion USD
MarketWatch	$12.51 Billion USD
marketcap.company	$12.51 Billion USD
Reuters	$12.51 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Biomarin Pharmaceutical Inc

NASDAQ:BMRN USA Biotechnology

Market Cap

$12.53 Billion

Market Cap Rank

#1879 Global

#710 in USA

Share Price

$64.73

Change (1 day)

+0.43%

52-Week Range

$49.67 - $70.24

All Time High

$131.03